Regulation of Tumor Microenvironment in Cancer
Regulation of Tumor Microenvironment in Cancer
批准号:
8856524
负责人:
SCOTT J. ANTONIA
金额:
$37.36万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-06-01 至 2017-05-31
关键词:
3-nitrotyrosineAddressAntibodiesAntigen PresentationAntigensApoptosisBindingCD8 AntigensCancer PatientCell physiologyCharacteristicsClinicalCysteineCytotoxic T-LymphocytesDataDevelopmentFree Radical FormationHealthHistocompatibility Antigens Class IImmuneImmune responseImmunotherapyInflammationInflammatory ResponseLung NeoplasmsMalignant NeoplasmsMalignant neoplasm of lungMethionineMethodsModelingMusMyelogenousMyeloid CellsNitric OxideNitrogenNon-Small-Cell Lung CarcinomaOxygenPatientsPeptide/MHC ComplexPeptidesPeripheralPeroxonitritePharmaceutical PreparationsPhase I/II TrialPlayProductionProteinsRecruitment ActivityRegulationResistanceRoleSamplingSignal TransductionSuperoxidesSuppressor-Effector T-LymphocytesSurfaceT cell responseT-Cell ReceptorT-LymphocyteTestingTissuesTryptophanTumor AntigensTumor EscapeTyrosineUp-RegulationVaccinesbasecancer cellcancer immunotherapyclinically relevantclinically significantgranulocyteimprovedinhibitor/antagonistkillingsmacrophagemouse modelneoplastic cellnitrationnovelnovel strategiespre-clinicalreceptorresponsesuccesstumortumor microenvironment
中文摘要
描述(申请人提供):近年来,癌症免疫治疗的进展使在接受各种癌症免疫治疗的患者中诱导肿瘤特异性免疫反应成为可能。然而,尽管取得了这些成功,从这些治疗中临床受益的患者比例仍然很小。很明显,肿瘤微环境甚至可以保护肿瘤免受强大的细胞毒性T细胞(CTL)反应的影响。与肿瘤微环境相关的炎症在肺癌的发生发展中起着重要作用。在炎症反应的背景下,髓系细胞是主要的招募效应器。产生活性氧(ROS)和氮(RNS)是所有激活的髓系细胞的主要特征之一。过氧亚硝酸根(PNT)自由基的形成是超氧化物和一氧化氮相互作用的主要结果。长期以来,酪氨酸残基的硝化一直被认为是PNT活性的标志。此外,PNT还可以与半胱氨酸、蛋氨酸和色氨酸直接反应。大量研究表明,肺癌中存在高水平的硝基酪氨酸(NT)。最近,我们提出了一个新的概念,可以解释炎症在肿瘤逃逸中的作用。肿瘤浸润性髓系细胞,尤其是髓系来源的抑制细胞,可以诱导肿瘤细胞表面MHC-I类分子的硝化,使肿瘤细胞不能有效地结合和保留多肽,从而使肿瘤细胞对抗原特异性CTL产生抵抗。这一概念表明,即使疫苗、T细胞转移或检查点抑制剂产生了针对肿瘤相关抗原的强大CTL反应,肿瘤也可能逃脱免疫控制。它还表明,可以通过使用ROS或RNS的药理抑制剂来阻止PNT的产生来减少这种逃逸。根据我们以前和初步的数据,我们认为抑制肿瘤微环境中的ROS和RNS可以增强肿瘤免疫治疗的效果。在本应用程序中,我们将检验这一假设。
具体目的:1.确定过氧亚硝酸根对肿瘤逃逸的作用机制;
具体目的2.在小鼠肿瘤模型中确定封闭PD1抗体与新的三萜类RTA 408的联合作用;
具体目的3.探讨肺肿瘤组织中活性氧和氮素类物质上调的临床意义。
英文摘要
DESCRIPTION (provided by applicant): In recent years, advances in cancer immunotherapy make it possible to induce tumor-specific immune responses in patients treated with various types of cancer immunotherapy. However, despite these successes, the proportion of patients who benefit clinically from these treatments remains small. It is clear that the tumor microenvironment may provide protection of tumors even against potent cytotoxic T cell (CTL) responses. Inflammation associated with the tumor microenvironment plays an important role in the development and progression of lung cancer. In the context of an inflammatory response myeloid cells are the primary recruited effectors. Production of reactive oxygen (ROS) and nitrogen (RNS) species is one of the major characteristics of all activated myeloid cells. The formation of the free radical peroxynitrite (PNT) is the main result of interaction between superoxide and nitric oxide. Nitration of tyrosine residues has long been recognized as a marker of PNT activity. In addition, PNT can react directly with cysteine, methionine and tryptophan. A substantial number of studies have demonstrated high levels of nitrotyrosine (NT) in lung cancer. Recently, we have proposed a novel concept that may explain the role of inflammation in tumor escape. The tumor-infiltrating myeloid cells, particularly myeloid-derived suppressor cells, can induce nitration of MHC class I molecules on tumor cells, making them unable to effectively bind and retain peptides and thus rendering the tumor cells resistant to antigen-specific CTLs. This concept suggests that tumors may escape immune control even if potent CTL responses against the tumor-associated antigens were generated either by vaccines, T-cell transfer, or checkpoint inhibitors. It also suggests that this escape can be diminished by blocking the PNT production using pharmacological inhibitors of ROS or RNS. Based on our previous and preliminary data we propose that inhibition of ROS and RNS in the tumor microenvironment can enhance the effect of cancer immune therapy. In this application we will test this hypothesis.
Specific aim 1. To determine the mechanism of peroxynitrite effects on tumor escape;
Specific aim 2. To determine in mouse tumor models the combine effect of a blocking PD1 antibody with a novel triterpenoid RTA 408;
Specific aim 3. To determine clinical significance of up-regulation of reactive oxygen and nitrogen species in lung tumors.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Novel roles of PCSK9 in regulating the tumor immune microenvironment during radiotherapy
-
批准号:10672976
-
项目类别:
-
资助金额:$52.44万
-
财政年份:2022
-
负责人:SCOTT J. ANTONIA
-
依托单位:
Eco-Evolutionary dynamics of NSCLC to immunotherapy: Response and Resistance
-
批准号:10478888
-
项目类别:
-
资助金额:$59.15万
-
财政年份:2018
-
负责人:SCOTT J. ANTONIA
-
依托单位:
Eco-Evolutionary dynamics of NSCLC to immunotherapy: Response and Resistance
-
批准号:9788320
-
项目类别:
-
资助金额:$65.08万
-
财政年份:2018
-
负责人:SCOTT J. ANTONIA
-
依托单位:
Eco-Evolutionary dynamics of NSCLC to immunotherapy: Response and Resistance
-
批准号:10005265
-
项目类别:
-
资助金额:$60.35万
-
财政年份:2018
-
负责人:SCOTT J. ANTONIA
-
依托单位:
Eco-Evolutionary dynamics of NSCLC to immunotherapy: Response and Resistance
-
批准号:10238921
-
项目类别:
-
资助金额:$75.7万
-
财政年份:2018
-
负责人:SCOTT J. ANTONIA
-
依托单位:
Targeting the adenosine A2A receptor immune checkpoint in lung cancer patients
-
批准号:9175600
-
项目类别:
-
资助金额:$32.17万
-
财政年份:2016
-
负责人:SCOTT J. ANTONIA
-
依托单位:
Targeting the adenosine A2A receptor immune checkpoint in lung cancer patients
-
批准号:9462266
-
项目类别:
-
资助金额:$18.92万
-
财政年份:2016
-
负责人:SCOTT J. ANTONIA
-
依托单位:
Development of Immunotherapeutic Strategies in the Treatment of Lung Cancer
-
批准号:7921307
-
项目类别:
-
资助金额:$10.96万
-
财政年份:2009
-
负责人:SCOTT J. ANTONIA
-
依托单位:
Development of Immunotherapeutic Strategies in the Treatment of Lung Cancer
-
批准号:8311051
-
项目类别:
-
资助金额:$17.12万
-
财政年份:2008
-
负责人:SCOTT J. ANTONIA
-
依托单位:
Development of Immunotherapeutic Strategies in the Treatment of Lung Cancer
-
批准号:7676762
-
项目类别:
-
资助金额:$16.45万
-
财政年份:2008
-
负责人:SCOTT J. ANTONIA
-
依托单位:
Development of Immunotherapeutic Strategies in the Treatment of Lung Cancer
-
批准号:8139718
-
项目类别:
-
资助金额:$17.12万
-
财政年份:2008
-
负责人:SCOTT J. ANTONIA
-
依托单位:
Development of Immunotherapeutic Strategies in the Treatment of Lung Cancer
-
批准号:7471963
-
项目类别:
-
资助金额:$16.13万
-
财政年份:2008
-
负责人:SCOTT J. ANTONIA
-
依托单位:
Combination Immunotherapy for Lung Cancer
-
批准号:7111269
-
项目类别:
-
资助金额:$28.93万
-
财政年份:2006
-
负责人:SCOTT J. ANTONIA
-
依托单位:
Combination Immunotherapy for Lung Cancer
-
批准号:7282732
-
项目类别:
-
资助金额:$28.09万
-
财政年份:2006
-
负责人:SCOTT J. ANTONIA
-
依托单位:
B7 1 GENE MODIFIED TUMOR CELL VACCINE FOR RENAL CELL CA
-
批准号:6153452
-
项目类别:
-
资助金额:$7.25万
-
财政年份:2000
-
负责人:SCOTT J. ANTONIA
-
依托单位:
B7 1 GENE MODIFIED TUMOR CELL VACCINE FOR RENAL CELL CA
-
批准号:6377276
-
项目类别:
-
资助金额:$7.25万
-
财政年份:2000
-
负责人:SCOTT J. ANTONIA
-
依托单位:
Precision Cancer Medicine and Investigational Therapeutics
-
批准号:10323317
-
项目类别:
-
资助金额:$6.72万
-
财政年份:1997
-
负责人:SCOTT J. ANTONIA
-
依托单位:
Precision Cancer Medicine and Investigational Therapeutics
-
批准号:10544834
-
项目类别:
-
资助金额:$6.76万
-
财政年份:1997
-
负责人:SCOTT J. ANTONIA
-
依托单位:
IMMUNE TOLERANCE INDUCTION BY A TUMOR SPECIFIC ANTIGEN
-
批准号:3086013
-
项目类别:
-
资助金额:$1.36万
-
财政年份:1994
-
负责人:SCOTT J. ANTONIA
-
依托单位:
IMMUNE TOLERANCE INDUCTION BY A TUMOR SPECIFIC ANTIGEN
-
批准号:2103305
-
项目类别:
-
资助金额:$9.42万
-
财政年份:1994
-
负责人:SCOTT J. ANTONIA
-
依托单位:
海外基金